In the last trading session, 0.13 million Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) shares changed hands as the company’s beta touched 0.66. With the company’s per share price at $1.71 changed hands at $0.06 or 3.82% during last session, the market valuation stood at $32.09M. CMMB’s last price was a discount, traded about -49.12% off its 52-week high of $2.55. The share price had its 52-week low at $0.45, which suggests the last value was 73.68% up since then. When we look at Chemomab Therapeutics Ltd ADR’s average trading volume, we note the 10-day average is 0.1 million shares, with the 3-month average coming to 118.37K.
Analysts gave the Chemomab Therapeutics Ltd ADR (CMMB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CMMB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) trade information
Instantly CMMB was in green as seen at the end of in last trading. With action 2.61%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 233.59%, with the 5-day performance at 2.61% in the green. However, in the 30-day time frame, Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) is 3.11% up. Looking at the short shares, we see there were 0.16 million shares sold at short interest cover period of 1.15 days.
Chemomab Therapeutics Ltd ADR (CMMB) estimates and forecasts
Data shows that the Chemomab Therapeutics Ltd ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 70.13% over the past 6 months, a 51.46% in annual growth rate that is considerably higher than the industry average of 16.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 37.62%. The 2024 estimates are for Chemomab Therapeutics Ltd ADR earnings to decrease by -178.32%.
CMMB Dividends
Chemomab Therapeutics Ltd ADR is expected to release its next quarterly earnings report in January.
